Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05740293 · ClinicalTrials.gov registry record
Post-approval Study of New Enrolment Patients Undergoing Bilateral Treatment With the VisuMax SMILE Procedure
A clinical trial, sponsored by Carl Zeiss Meditec.
- Completed
- Registry status
- 186
- Enrollment target
NCT05740293: Completed study, sponsored by Carl Zeiss Meditec.
NCT05740293 is a clinical trial that has completed, run by Carl Zeiss Meditec. The registered enrollment target is 186 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05740293 has completed, sponsored by Carl Zeiss Meditec.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
Study Summary
The objective of the post-approval study (PAS) is to assess patient experience of visual symptoms 6 months after bilateral treatment with the VisuMax SMILE procedure as measured by a patient questionnaire.
Primary Outcome
* Proportion of subjects that developed "very" or "extremely" bothersome visual symptoms from preoperative (with optical correction) to 6 months postoperatively (without optical correction) * Proportion of subjects that developed difficulty performing daily activities (2 highest categories) due to visual symptoms from preoperative (with optical correction) to 6 months postoperatively (without optical correction)
Interventions
- PROCEDURE VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2025-08-25 |
What the finished NCT05740293 record still lists
NCT05740293 is an observational study that tracks outcomes without assigning an intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism is the first listed.
NCT05740293 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05740293 about?
NCT05740293 is a clinical study titled "Post-approval Study of New Enrolment Patients Undergoing Bilateral Treatment With the VisuMax SMILE Procedure". The objective of the post-approval study (PAS) is to assess patient experience of visual symptoms 6 months after bilateral treatment with the VisuMax SMILE procedure as measured by a patient questionnaire.
What is the current status of trial NCT05740293?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2022-04-05. Estimated completion is 2025-08-25.
What interventions are being tested in trial NCT05740293?
The interventions under investigation include: VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism (PROCEDURE).
Who is sponsoring clinical trial NCT05740293?
This trial is sponsored by Carl Zeiss Meditec, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI